Atezolizumab is an immune checkpoint inhibitor that acts by blocking PD-L1 (anti-programmed death-1), an inhibitory receptor expressed on activated T cells under conditions of prolonged stimulation, such as infection or cancer [41]. Here, CD274 is linked to cancer.